# Title

 Food and Drugs. PART 607â€”ESTABLISHMENT REGISTRATION AND PRODUCT LISTING FOR MANUFACTURERS OF HUMAN BLOOD AND BLOOD PRODUCTS AND LICENSED DEVICES


# ID

 CFR-2018-title21-vol7.Pt. 607


# Structured Analysis Summary

| Type        | Values                                                                                                           |
|:------------|:-----------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'after', 'minimum', 'prior to']                                                |
| Duration    | ['5.0 day', '30.0 day']                                                                                          |
| Condition   | ['not subject to', 'unless', 'where', 'subject to', 'when', 'if']                                                |
| Entities    | ['United States', 'Public', 'Scope', 'Blood', 'Outreach', 'Food', 'English', 'Rm', 'Research', 'U.S', 'Freedom'] |
| Date        | ['2018-12-01', '1938-06-25', '2018-10-01', '2018-12-31', '2018-06-01']                                           |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                          |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------------|
| after         | from human whole blood, plasma, or serum, herein after referred to as &#8220;blood product.&#8221; For the purposes              |
| within        | of a bulk product substance between registered establishments within  the same parent, subsidiary, and/or affiliate company.     |
| more than     | for all establishments when operations are conducted at more than one establishment and there exists joint ownership and         |
| before        | to manufacture blood products are required to register before  the biologics license application is approved.                    |
| within        | determination that a blood product is a &#8220;drug&#8221; within  the meaning of section 201(g) of the act.                     |
| within        | operation defined in &#167;&#8201;607.3(d) shall register such establishment within 5 days after the beginning of such operation |
| after         | &#167;&#8201;607.3(d) shall register such establishment within 5 days after the beginning of such operation and submit a         |
| within        | which a license is required, registration shall follow within 5 days after the submission of a biologics                         |
| after         | is required, registration shall follow within 5 days after the submission of a biologics license application in                  |
| prior to      | granted a request for waiver of this requirement prior to  the date on which the information is due.                             |
| within        | superseding electronic system, as an amendment to registration within  5 calendar days of such changes.                          |
| after         | not been included in any list previously submitted. after                                                                        |
| minimum       | or any future superseding electronic system, at a minimum once in June and December of every year,                               |
| within        | address, telephone number, or email address to FDA within  30 calendar days of the change.                                       |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                          |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.0 day    | The owner or operator of an establishment entering into an operation defined in &#167;&#8201;607.3(d) shall register such establishment within 5 days after the beginning of such operation and submit a list of every blood product in commercial distribution at the time.                                                                     |
| 5.0 day    | If the owner or operator of the establishment has not previously entered into such operation (defined in &#167;&#8201;607.3(d) of this chapter) for which a license is required, registration shall follow within 5 days after the submission of a biologics license application in order to manufacture blood products.                         |
| 5.0 day    | Changes in individual ownership, corporate or partnership structure, location, or blood product handling activity must be submitted electronically through the Blood Establishment Registration and Product Listing system, or any future superseding electronic system, as an amendment to registration within 5 calendar days of such changes. |
| 30.0 day   | (3) The foreign establishment or the United States agent must report changes in the United States agent's name, address, telephone number, or email address to FDA within 30 calendar days of the change.                                                                                                                                        |


## Condition

| Condition      | Context                                                                                                                             |
|:---------------|:------------------------------------------------------------------------------------------------------------------------------------|
| where          | the quantity or identity of the inactive ingredient(s) where quantitative listing of all ingredients is required pursuant           |
| when           | represented for use in a blood product and when used in the manufacturing of a blood product                                        |
| when           | the act shall be applicable to such terms when  used in this part 607.                                                              |
| where          | mailboxes, answering machines or services, or other places where an individual acting as the foreign establishment's agent          |
| when           | purpose of registration and listing under this part when used to modify the term &#8220;establishment&#8221; refers to              |
| where          | in a foreign country and is the site where a blood product that is imported or offered                                              |
| when           | parent, subsidiary, and/or affiliate company for all establishments when operations are conducted at more than one establishment    |
| unless         | this part must be transmitted to FDA electronically unless FDA has granted a request for waiver of                                  |
| if             | FDA will grant a waiver request  if FDA determines that the use of electronic means                                                 |
| where          | and a U.S. telephone number and mailing address where  FDA can contact the registrant.                                              |
| if             | FDA may limit its duration and will spec if y terms of the waiver and provide information                                           |
| if             | establishment, including post office code; a registration number if previously assigned by FDA and a Unique Facility                |
| if             | Drug, and Cosmetic Act and by proprietary name, if any, which are being manufactured for commercial distribution                    |
| subject to     | For each blood product so listed that is subject to section 351 of the Public Health Service Act,                                   |
| if             | For each blood product listed, the registration number if previously assigned by FDA and the Unique Facility                        |
| when           | previously submitted list, no listing information is required. when                                                                 |
| unless         | requirements contained in subpart B of this part, unless  exempt under subpart D of this part or                                    |
| unless         | requirements contained in subpart B of this part, unless  exempt under subpart D of this part or                                    |
| unless         | or offered for import into the United States unless it is the subject of a blood product                                            |
| unless         | Product Listing system, or any superseding electronic system, unless FDA waives the electronic submission requirement in accordance |
| not subject to | of in vitro diagnostic blood products and reagents not subject to licensing under section 351 of the Public Health                  |
| unless         | with respect to their manufacture of those products, unless  otherwise noted in this section.                                       |


## Entities

| Entities      | Context                                                                                                                          |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                                                                                 |
| Scope         | Scope .                                                                                                                          |
| United States | neither imported nor offered for import into the United States .                                                                 |
| United States | (j)  United States agent means a person residing or maintaining a                                                                |
| United States | (j)  United States agent means a person residing or maintaining a                                                                |
| United States | (k) Importer means a person in the  United States that is an owner, consignee, or recipient, at                                  |
| United States | (k) Importer means a person in the  United States that is an owner, consignee, or recipient, at                                  |
| United States | is imported or offered for import into the United States  was manufactured.                                                      |
| Blood         | Blood products manufactured, prepared, propagated, compounded, or processed in                                                   |
| U.S           | is not reasonable for the registrant and a U.S . telephone number and mailing address where FDA                                  |
| Research      | issued by the Center for Biologics Evaluation and Research , Food and Drug Administration.                                       |
| Public        | Public disclosure of establishment registration and blood product listing                                                        |
| Research      | disclosure through the Center for Biologics Evaluation and Research (CBER) Blood Establishment Registration Database Web site by |
| Freedom       | to the Food and Drug Administration, Division of Freedom of Information Public Reading Room (see addresses in                    |
| Outreach      | for Biologics Evaluation and Research Office of Communication, Outreach , and Development, 10903 New Hampshire Ave., Bldg.       |
| Rm            | 71,  Rm .                                                                                                                        |
| United States | be imported or offered for import into the United States unless it is the subject of a blood                                     |
| English       | blood product listing information shall be in the English  language.                                                             |
| United States | address, telephone number, and email address of its United States agent as part of its initial and updated                       |
| United States | Each foreign establishment must designate only one  United States  agent.                                                        |
| United States | (1) The  United States agent shall reside or maintain a place of                                                                 |
| United States | (1) The  United States agent shall reside or maintain a place of                                                                 |
| United States | (2) Upon request from FDA, the  United States agent shall assist FDA in communications with the                                  |
| United States | (2) Upon request from FDA, the  United States agent shall assist FDA in communications with the                                  |
| United States | FDA may provide information or documents to the United States agent, and such an action shall be considered                      |
| United States | (3) The foreign establishment or the  United States  agent must report changes in the                                            |
| United States | (3) The foreign establishment or the  United States  agent must report changes in the                                            |
| Food          | of the act, or because the Commissioner of Food and Drugs has found, under section 510(g)(5), that                               |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1938-06-25 | (a) The term act means the Federal Food, Drug, and Cosmetic Act approved June 25, 1938 (52 Stat.                                                                                                                                                                                                                                                                                       |
| 2018-10-01 | Owners or operators of all establishments so engaged must register annually between October 1 and December 31 and must update their blood product listing every June and December.                                                                                                                                                                                                     |
| 2018-12-31 | Owners or operators of all establishments so engaged must register annually between October 1 and December 31 and must update their blood product listing every June and December.                                                                                                                                                                                                     |
| 2018-06-01 | Owners or operators of all establishments so engaged must register annually between October 1 and December 31 and must update their blood product listing every June and December.                                                                                                                                                                                                     |
| 2018-06-01 | (a) After submission of the initial blood product listing information, every person who is required to list blood products under &#167;&#8201;607.20 must submit electronically through the Blood Establishment Registration and Product Listing system, or any future superseding electronic system, at a minimum once in June and December of every year, the following information: |
|            |               (1) A list of each blood product introduced by the registrant for commercial distribution which has not been included in any list previously submitted.                                                                                                                                                                                                                  |
| 2018-12-01 | (a) After submission of the initial blood product listing information, every person who is required to list blood products under &#167;&#8201;607.20 must submit electronically through the Blood Establishment Registration and Product Listing system, or any future superseding electronic system, at a minimum once in June and December of every year, the following information: |
|            |               (1) A list of each blood product introduced by the registrant for commercial distribution which has not been included in any list previously submitted.                                                                                                                                                                                                                  |


